ASX Announcement

Military Health System Research Symposium Abstract & Poster Presentation

SYDNEY Australia, 3 June 2024: Recce Pharmaceuticals Ltd (**ASX:RCE**, **FSE:R9Q**) (the **Company**), the Company developing a new class of Synthetic Anti-infectives, has received confirmation a research Abstract and Poster presentation will be published at the 2024 Military Health System Research Symposium (MHSRS).

The Abstract & Poster publications will be accompanied by an in-person, oral presentation by Dr John Prendergast, Executive Chairman and Alan W. Dunton MD, Non-Executive Director and Chief Medical Advisor of Recce Pharmaceuticals Ltd. The speaking session focuses on Non-traditional Treatments and Delivery strategies for Wound infections and Sepsis. The abstract presents expanded details of RECCE® 327 demonstrating rapid bactericidal activity against *Streptococcus pyogenes* and *Clostridium perfringens* in a preclinical time-kill experiment and diabetic foot wound infections when applied topically to patients.

Session

Non-traditional Treatments and Delivery strategies for Wound infections and Sepsis

Title

RECCE® 327 Demonstrates Bactericidal Activity Against Multi-Drug Resistant Pathogens and Clinical Efficacy in Polymicrobial Wound Infections

The MHSRS is the United States (US) Department of Defence's foremost scientific meeting. It provides a venue for presenting new scientific knowledge particular to military specific focuses in research and development. The MHSRS is the premier US military and select civilian meeting that draws approximately 4,000 attendees with focus to the unique medical needs of the Warfighter. The symposium will be held in Kissimmee, Florida 26-29 August 2024.

A non-confidential version of the Poster and Abstract materials will be available on the Company's website, post-conference.

As a result of the Company's efforts in the military sector, the Company announced on the 8th of April 2024, the US Department of Defence has Recommended R327 Gel (R327G) as a topical treatment for Burn Wound Infections for grant funding of USD $2.2 million (AUD 3.34 million).

Once awarded, the funding will enable the Company to accelerate the development and evaluation of R327G and evaluate it as a gel-based treatment to rapidly resolve burn wound infections and minimise the onset of bacteraemia complications, such as sepsis.

This milestone emphasises the Company's significant contributions to military health research.

This announcement has been approved for release by Recce Pharmaceuticals Board.

recce.com.au
ACN 124 849 065

Chief Executive Officer
James Graham
Recce Pharmaceuticals Ltd
james.graham@recce.com.au

Media and Investor Relations

Australia
Andrew Geddes
CityPR
+61 408 677 734
ageddes@citypublicrelations.com.au

USA
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com

Europe
Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

recce.com.au
ACN 124 849 065

Media and Investor Relations

Chief Executive Officer
James Graham
Recce Pharmaceuticals Ltd
james.graham@recce.com.au

Australia
Andrew Geddes
CityPR
+61 408 677 734
ageddes@citypublicrelations.com.au

USA
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com

Europe
Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com